Intra-Cellular Therapies to be Added to the Russell 3000(R) and Russell
NEW YORK, June 27, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.
(Nasdaq:ITCI), a biopharmaceutical company focused on the development of
therapeutics for central nervous system (CNS) disorders, announced that it
will be added to the Russell 3000^® and Russell 2000^® Indexes today, Friday,
June 27, 2014, when Russell Investments reconstitutes its comprehensive set of
U.S. and global equity indexes.
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest
U.S. stocks as of the end of May, ranking them by total market capitalization.
A one-year membership in the Russell 3000 means automatic inclusion in the
small-cap Russell 2000 Index, as well as the appropriate growth and value
style indexes. Russell determines membership for its equity indexes primarily
by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Russell calculates more than 700,000 benchmarks daily
covering approximately 98 percent of the investable market globally, 80
countries and more than 10,000 securities. Approximately $4.1 trillion in
assets are benchmarked to the Russell Indexes.
About Intra-Cellular Therapies
Intra-Cellular Therapies (the "Company") is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative disease and other
disorders of the central nervous system ("CNS"). The Company is developing its
lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral
disturbances in dementia, bipolar disorder and other neuropsychiatric and
neurological disorders. In December 2013, the Company announced positive
topline results from the Company's randomized, placebo- and active-controlled
Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated
schizophrenia. This study showed a statistically significant improvement in
symptoms associated with schizophrenia at the 60 mg dose on the trial's
pre-specified primary endpoint and a favorable safety profile. The Company is
exploring lower doses of ITI-007 for the treatment of behavioral disturbances
in dementia and related disorders. ITI-007 is in a Phase 1/2 safety,
tolerability and pharmacokinetic clinical study in elderly patients and in
geriatric subjects with and without dementia. The Company is also utilizing
its phosphodiesterase ("PDE") platform and other proprietary chemistry
platforms to develop drugs for the treatment of cognitive deficits in
schizophrenia and other CNS disorders. The Company has partnered its lead PDE1
compound, ITI-214, and backups from this platform with the Takeda
Pharmaceutical Company. ITI-214 has finished the first Phase 1 clinical trial
and is now in subsequent Phase 1 trials. The Company is also developing
inhibitors against additional targets for CNS indications such as Alzheimer's
disease, Parkinson's disease and depression and non-CNS indications such as
CONTACT: Juan Sanchez, M.D.
Corporate Communications and Investor Relations
of Intra-Cellular Therapies, Inc.
Burns McClellan, Inc.
Lisa Burns/Angeli Kolhatkar (Investors)
Justin Jackson (Media)
Intra-Cellular Therapies logo
Press spacebar to pause and continue. Press esc to stop.